Entera Bio Ltd. Repayment/Issuance of Debt (Net)

Repayment/Issuance of Debt (Net) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Repayment/Issuance of Debt (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Repayment/Issuance of Debt (Net) for the quarter ending June 29, 2020 was $-35 Thousand (a -5.41% decrease compared to previous quarter)
  • Year-over-year quarterly Repayment/Issuance of Debt (Net) increased by 16.67%
  • Annual Repayment/Issuance of Debt (Net) for 2019 was $-114 Thousand (a -88.37% decrease from previous year)
  • Twelve month Repayment/Issuance of Debt (Net) ending June 29, 2020 was $-134 Thousand (a 4.69% increase compared to previous quarter)
  • Twelve month trailing Repayment/Issuance of Debt (Net) increased by 63.41% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-134 Thousand $-128 Thousand $-114 Thousand $-82 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Repayment/Issuance of Debt (Net) of Entera Bio Ltd.

Most recent Repayment/Issuance of Debt (Net)of ENTX including historical data for past 10 years.

Interactive Chart of Repayment/Issuance of Debt (Net) of Entera Bio Ltd.

Entera Bio Ltd. Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.04 $-0.04
2019 $-0.03 $-0.03 $-0.03 $-0.02 $-0.11
2018 $0.0
2017 $-0.98 $-0.98

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.